Moderna to start first human trials of mRNA vaccine against HIV
Updated: 2021-08-27 17:07:15 KST
MRNA vaccines have been a major success in protecting people from COVID-19.
Now scientists are looking into other applications for this technology that could be revolutionary.
"The mRNA vaccine is something that hasn't been used for HIV yet, so there is optimism that they will be able to develop a vaccine against HIV, but we have to wait until we actually see good results from it."
Scientists have spent more than three decades and billions of dollars to develop a vaccine to stop HIV, but sadly to no avail.
This mRNA technology, however, opens up a new door of hope.
Moderna will start the first human trials of an mRNA vaccine against HIV on 56 uninfected adults as early as next month.
The trials will end in 2023, and although no one knows what the results will be, scientists are hopeful because mRNA vaccines have shown promising results in reducing HIV risk for primates.
MRNA technology also has an edge over other vaccine technologies in that it's easily modifiable, so it can potentially protect against the numerous HIV mutations.
Scientists are using mRNA to develop not only vaccines against viruses but also treatments for cancer.
"One of the challenges with cancer cells is that they're essentially normal cells that have gone haywire. So that if we can identify the thing that's on the surface on these cancer cells, just like we identified these spike proteins on the virus then that's a potential opportunity."